交易 Medivir B - MVIRb CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
价差 | 0.72 | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.019721% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | -0.002501% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | SEK | ||||||||
保证金 | 20% | ||||||||
上市交易所 | Sweden | ||||||||
交易费 | 0% |
*Information provided by Capital.com
Medivir AB ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平仓 | Change | Change (%) | 開倉 | High | Low |
---|---|---|---|---|---|---|
May 26, 2023 | 6.88 | 0.00 | 0.00% | 6.88 | 6.88 | 6.88 |
May 15, 2023 | 6.88 | 0.24 | 3.61% | 6.64 | 6.88 | 6.64 |
May 12, 2023 | 7.02 | -0.14 | -1.96% | 7.16 | 7.16 | 7.02 |
May 11, 2023 | 7.02 | 0.00 | 0.00% | 7.02 | 7.02 | 7.02 |
May 10, 2023 | 7.00 | -0.02 | -0.28% | 7.02 | 7.02 | 7.00 |
May 9, 2023 | 7.02 | 0.04 | 0.57% | 6.98 | 7.02 | 6.98 |
May 8, 2023 | 6.98 | 0.06 | 0.87% | 6.92 | 6.98 | 6.92 |
May 3, 2023 | 7.26 | 0.00 | 0.00% | 7.26 | 7.26 | 7.26 |
May 2, 2023 | 7.32 | 0.00 | 0.00% | 7.32 | 7.32 | 7.32 |
Apr 26, 2023 | 7.06 | -0.18 | -2.49% | 7.24 | 7.24 | 7.00 |
Apr 25, 2023 | 7.22 | 0.04 | 0.56% | 7.18 | 7.26 | 7.18 |
Apr 24, 2023 | 7.24 | 0.00 | 0.00% | 7.24 | 7.28 | 7.24 |
Apr 21, 2023 | 7.24 | -0.04 | -0.55% | 7.28 | 7.28 | 7.24 |
Apr 20, 2023 | 7.28 | 0.00 | 0.00% | 7.28 | 7.28 | 7.28 |
Apr 11, 2023 | 7.26 | 0.00 | 0.00% | 7.26 | 7.26 | 7.26 |
Mar 29, 2023 | 7.26 | 0.00 | 0.00% | 7.26 | 7.26 | 7.26 |
Mar 22, 2023 | 8.04 | 0.00 | 0.00% | 8.04 | 8.04 | 8.04 |
Mar 7, 2023 | 8.04 | 0.00 | 0.00% | 8.04 | 8.04 | 8.04 |
Feb 23, 2023 | 8.04 | 0.00 | 0.00% | 8.04 | 8.04 | 8.04 |
Feb 22, 2023 | 8.04 | 0.00 | 0.00% | 8.04 | 8.04 | 8.04 |
Medivir B Events
时间(协调世界时) (UTC) | 国家/地区 | 事件 |
---|---|---|
Friday, August 18, 2023 | ||
时间(协调世界时) (UTC) 06:30 | 国家/地区 SE
| 事件 Q2 2023 Medivir AB Earnings Release Q2 2023 Medivir AB Earnings ReleaseForecast -Previous - |
Friday, November 3, 2023 | ||
时间(协调世界时) (UTC) 07:30 | 国家/地区 SE
| 事件 Q3 2023 Medivir AB Earnings Release Q3 2023 Medivir AB Earnings ReleaseForecast -Previous - |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
总收入 | 4.408 | 25.538 | 13.948 | 8.724 | 23.863 |
收入 | 4.408 | 25.538 | 13.948 | 8.724 | 23.863 |
收入成本,共计 | 69.078 | 66.421 | 46.45 | 91.063 | 235.129 |
毛利 | -64.67 | -40.883 | -32.502 | -82.339 | -211.266 |
总营业费用 | 91.762 | 87.656 | 56.848 | 134.703 | 374.893 |
销售/一般/行政费用,总计 | 20.735 | 21.415 | 24.931 | 35.033 | 118.177 |
研究与开发 | |||||
Depreciation / Amortization | 2.571 | 2.595 | 4.43 | 7.085 | 24.532 |
Other Operating Expenses, Total | 0.632 | -0.495 | -16.318 | 1.522 | -2.945 |
营业收入 | -87.354 | -62.118 | -42.9 | -125.979 | -351.03 |
利息收入(费用),非经营净值 | -1.411 | -0.46 | 0.28 | 2.644 | 0.555 |
税前净收入 | -88.765 | -62.579 | -42.62 | -123.334 | -350.475 |
税后净收入 | -88.765 | -63.125 | -42.62 | -123.44 | -350.314 |
未计算非常项目前的净收益 | -88.765 | -63.125 | -42.62 | -123.44 | -350.314 |
非常规项目总计 | |||||
净收入 | -88.765 | -63.125 | -42.62 | -123.44 | -350.314 |
普通股股东可获收益 (不含非经常性项目) | -88.765 | -63.125 | -42.62 | -123.44 | -350.314 |
普通股股东可获收益 (含非經常性項目) | -88.765 | -63.125 | -42.62 | -123.44 | -350.314 |
摊薄调整 | |||||
摊薄净收入 | -88.765 | -63.125 | -42.62 | -123.44 | -350.314 |
摊薄后加权平均股 | 55.736 | 52.815 | 29.5798 | 29.5798 | 29.1755 |
扣除特别项目的每股摊薄盈利 | -1.5926 | -1.19521 | -1.44085 | -4.17311 | -12.0071 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
每股正常摊薄盈利 | -1.59323 | -1.20358 | -1.48676 | -4.17311 | -12.0062 |
异常费用(收入) | -0.035 | -0.68 | -1.358 | 0 | 0 |
Total Adjustments to Net Income | |||||
其他,净值 | -0.001 | 0.001 | |||
利息费用(收入) - 净运营 | -1.219 | -1.6 | -1.287 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
总收入 | 0.4 | 2.308 | 1.1 | 0.5 | 0.5 |
收入 | 0.4 | 2.308 | 1.1 | 0.5 | 0.5 |
收入成本,共计 | 13.1 | 15.778 | 11.1 | 16.4 | 25.8 |
毛利 | -12.7 | -13.47 | -10 | -15.9 | -25.3 |
总营业费用 | 20 | 20.962 | 15.7 | 22.6 | 32.5 |
销售/一般/行政费用,总计 | 6.2 | 4.735 | 3.9 | 5.8 | 6.2 |
Depreciation / Amortization | 0.7 | 0.671 | 0.7 | 0.6 | 0.6 |
Other Operating Expenses, Total | 0 | -0.222 | 0 | -0.2 | -0.1 |
营业收入 | -19.6 | -18.654 | -14.6 | -22.1 | -32 |
利息收入(费用),非经营净值 | 0.7 | 0.489 | -0.2 | -1.1 | -0.7 |
税前净收入 | -18.9 | -18.065 | -14.8 | -23.1 | -32.7 |
税后净收入 | -18.9 | -18.065 | -14.8 | -23.1 | -32.7 |
未计算非常项目前的净收益 | -18.9 | -18.065 | -14.8 | -23.1 | -32.7 |
净收入 | -18.9 | -18.065 | -14.8 | -23.1 | -32.7 |
普通股股东可获收益 (不含非经常性项目) | -18.9 | -18.065 | -14.8 | -23.1 | -32.7 |
普通股股东可获收益 (含非經常性項目) | -18.9 | -18.065 | -14.8 | -23.1 | -32.7 |
摊薄净收入 | -18.9 | -18.065 | -14.8 | -23.1 | -32.7 |
摊薄后加权平均股 | 55.736 | 55.736 | 55.736 | 55 | 55.736 |
扣除特别项目的每股摊薄盈利 | -0.3391 | -0.32412 | -0.26554 | -0.42 | -0.58669 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
每股正常摊薄盈利 | -0.3391 | -0.32412 | -0.26554 | -0.42 | -0.58669 |
其他,净值 | 0.1 | 0.1 | |||
Total Adjustments to Net Income |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流动资产总额 | 123.044 | 225.917 | 78.931 | 152.811 | 311.64 |
现金和短期投资 | 117.434 | 221.167 | 70.007 | 134.509 | 286.281 |
Cash | 6.448 | 14.69 | 14.038 | 34.3 | 47.175 |
短期投资 | 110.986 | 206.477 | 55.969 | 100.209 | 239.106 |
应收账款总额,净额 | 2.826 | 2.74 | 3.992 | 11.557 | 5.538 |
Accounts Receivable - Trade, Net | 0.001 | 0 | 0.015 | 0.063 | 0.159 |
Total Inventory | |||||
Prepaid Expenses | 2.784 | 2.01 | 4.932 | 6.745 | 19.82 |
Total Assets | 234.197 | 335.825 | 191.462 | 293.462 | 419.352 |
Property/Plant/Equipment, Total - Net | 14.841 | 13.597 | 16.211 | 23.283 | 10.828 |
Property/Plant/Equipment, Total - Gross | 33.143 | 21.356 | 28.658 | 38.416 | 106.498 |
Accumulated Depreciation, Total | -18.302 | -7.76 | -12.447 | -15.133 | -95.67 |
Goodwill, Net | |||||
Intangibles, Net | 96.312 | 96.312 | 96.32 | 96.341 | 96.885 |
Other Long Term Assets, Total | -0.001 | -0.001 | |||
Total Current Liabilities | 28.009 | 41.716 | 34.67 | 54.974 | 96.983 |
Accounts Payable | 3.763 | 10.338 | 6.808 | 12.303 | 16.335 |
Accrued Expenses | 8.11 | 29.171 | 25.414 | 30.016 | 50.64 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 14.023 | 1.153 | 0.848 | 5.926 | 30.008 |
Total Liabilities | 41.408 | 54.679 | 49.557 | 109.006 | 111.746 |
Total Long Term Debt | 13.399 | 12.964 | 14.888 | 37.153 | 0 |
Deferred Income Tax | 0 | ||||
Total Equity | 192.789 | 281.146 | 141.905 | 184.456 | 307.606 |
Common Stock | 27.868 | 27.868 | 188.494 | 188.494 | 188.494 |
Additional Paid-In Capital | 805.349 | 804.944 | 420.804 | 420.208 | 420.208 |
Retained Earnings (Accumulated Deficit) | -637.184 | -548.419 | -463.655 | -421.035 | -297.595 |
Other Equity, Total | -3.244 | -3.247 | -3.738 | -3.211 | -3.501 |
Total Liabilities & Shareholders’ Equity | 234.197 | 335.825 | 191.462 | 293.462 | 419.352 |
Total Common Shares Outstanding | 55.7242 | 55.7242 | 29.5796 | 29.5796 | 29.5797 |
Other Current Assets, Total | 0.001 | ||||
Other Liabilities, Total | -0.001 | -0.001 | 16.879 | 14.763 | |
Note Receivable - Long Term | 0 | 0 | 21.027 | ||
Current Port. of LT Debt/Capital Leases | 2.113 | 1.054 | 1.6 | 6.729 | |
Capital Lease Obligations | 13.399 | 12.964 | 14.888 | 37.153 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
流动资产总额 | 105.7 | 123.044 | 147.5 | 168.2 | 185.7 |
现金和短期投资 | 100.8 | 117.434 | 142.2 | 162.8 | 180.8 |
Cash | 4.9 | 6.448 | 7 | 4.6 | 4.8 |
短期投资 | 95.9 | 110.986 | 135.2 | 158.2 | 176 |
应收账款总额,净额 | 4.9 | 2.826 | 5.3 | 5.4 | 4.9 |
Accounts Receivable - Trade, Net | 4.9 | 0.001 | 5.3 | 5.4 | 4.9 |
Total Assets | 216.2 | 234.197 | 259.3 | 276.9 | 295 |
Property/Plant/Equipment, Total - Net | 14.1 | 14.841 | 15.5 | 12.4 | 13 |
Intangibles, Net | 96.3 | 96.312 | 96.3 | 96.3 | 96.3 |
Note Receivable - Long Term | |||||
Other Long Term Assets, Total | 0.1 | ||||
Total Current Liabilities | 29.4 | 28.009 | 33.9 | 39.5 | 34.1 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 29.4 | 1.46 | 33.9 | 39.5 | 34.1 |
Total Liabilities | 42.3 | 41.408 | 48.8 | 51.6 | 46.6 |
Total Long Term Debt | 12.8 | 13.399 | 14.9 | 12.1 | 12.5 |
Capital Lease Obligations | 12.8 | 13.399 | 14.9 | 12.1 | 12.5 |
Total Equity | 173.9 | 192.789 | 210.5 | 225.3 | 248.4 |
Common Stock | 27.9 | 27.868 | 27.9 | 27.9 | 27.9 |
Additional Paid-In Capital | 805.3 | 805.349 | 804.9 | 804.9 | 804.9 |
Retained Earnings (Accumulated Deficit) | -656.1 | -637.184 | -619.1 | -604.3 | -581.2 |
Other Equity, Total | -3.2 | -3.244 | -3.2 | -3.2 | -3.2 |
Total Liabilities & Shareholders’ Equity | 216.2 | 234.197 | 259.3 | 276.9 | 295 |
Total Common Shares Outstanding | 55.7246 | 55.7242 | 55.7246 | 55.7246 | 55.7246 |
Prepaid Expenses | 2.784 | ||||
Other Liabilities, Total | 0.1 | ||||
Accounts Payable | 3.763 | ||||
Accrued Expenses | 20.673 | ||||
Current Port. of LT Debt/Capital Leases | 2.113 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
净收入/起跑线 | -88.765 | -62.579 | -42.62 | -123.334 | -350.475 |
经营活动产生的现金 | -101.82 | -48.734 | -58.053 | -148.255 | -318.63 |
经营活动产生的现金 | 2.571 | 2.595 | 4.43 | 7.086 | 26.304 |
非现金物品 | 0 | -16.968 | -18.293 | 30.583 | |
Cash Taxes Paid | 0 | 1.214 | -0.799 | -1.946 | -2.987 |
已付现金利息 | 1.315 | 0.015 | |||
营运资金的变化 | -15.626 | 11.25 | -2.895 | -13.714 | -25.042 |
投资活动产生的现金 | -0.382 | 0 | 5.368 | 4.49 | -6.838 |
资本支出 | -0.382 | 0 | -2.684 | -1.436 | -6.838 |
其他投资现金流量项目,总计 | 0 | 8.052 | 5.926 | ||
融资活动产生的现金 | -1.535 | 199.4 | -12.118 | -6.659 | 143.79 |
融资现金流项目 | 0.001 | -24.115 | -12.713 | -6.659 | -11.287 |
股票的发行(报废),净额 | 0.404 | 223.515 | 0.595 | 0 | 155.077 |
外汇效应 | 0.003 | 0.494 | 0.301 | -1.349 | 0.18 |
现金净变化 | -103.734 | 151.16 | -64.502 | -151.773 | -181.498 |
债务的发行(退还),净额 | -1.94 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Cash From Operating Activities | -16.1 | -101.82 | -77.1 | -57.5 | -39.9 |
Changes in Working Capital | -16.1 | -101.82 | -77.1 | -57.5 | -39.9 |
Cash From Investing Activities | 0 | -0.382 | -0.4 | 0 | 0 |
Other Investing Cash Flow Items, Total | |||||
Cash From Financing Activities | -0.5 | -1.535 | -1.4 | -1 | -0.5 |
Financing Cash Flow Items | -0.5 | 0.001 | -1.4 | -1 | -0.5 |
Issuance (Retirement) of Stock, Net | 0 | 0.404 | 0 | 0 | |
Foreign Exchange Effects | 0 | 0.003 | 0 | 0 | 0 |
Net Change in Cash | -16.6 | -103.734 | -78.9 | -58.5 | -40.4 |
Capital Expenditures | 0 | -0.382 | -0.4 | 0 | 0 |
Issuance (Retirement) of Debt, Net | -1.94 |
投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
---|---|---|---|---|---|---|
Julander (Bengt) | Individual Investor | 12.2493 | 6840172 | 0 | 2022-09-30 | LOW |
Avanza Bank Holding AB | Holding Company | 10.57 | 5902425 | 308149 | 2022-09-30 | LOW |
Nordea Funds Oy | Investment Advisor | 8.5515 | 4775296 | -331344 | 2023-02-28 | LOW |
Healthinvest Partners AB | Investment Advisor/Hedge Fund | 6.2857 | 3510000 | 0 | 2022-09-30 | MED |
Nordnet Pensionsforsakring AB | Corporation | 2.8118 | 1570173 | -262681 | 2022-09-30 | LOW |
Ålandsbanken Asset Management Ab | Investment Advisor | 2.037 | 1137481 | 0 | 2022-09-30 | LOW |
N.G.L. Förvaltning AB | Corporation | 1.7908 | 1000000 | 0 | 2022-09-30 | |
Bank Julius Bär & Co. AG | Bank and Trust | 1.5926 | 889350 | 0 | 2022-09-30 | LOW |
Nydah (Jan Stefan) | Individual Investor | 1.3251 | 739954 | 0 | 2022-09-30 | |
SEB Investment Management AB | Investment Advisor | 1.1461 | 640000 | 0 | 2022-09-30 | LOW |
Jonsson (Jonas Fredrik) | Individual Investor | 0.9226 | 515201 | 515201 | 2021-12-30 | |
Gryningskust Holding AB | Corporation | 0.8417 | 470000 | 0 | 2022-09-30 | |
Öberg (Bo) | Individual Investor | 0.8018 | 447744 | 0 | 2022-09-30 | |
Banque Pictet & Cie S.A. | Investment Advisor | 0.7178 | 400826 | 0 | 2022-09-30 | LOW |
Hacksell (Uli) | Individual Investor | 0.4477 | 250000 | 100000 | 2021-12-30 | |
Öberg (Fredrik) | Individual Investor | 0.1239 | 69172 | 0 | 2021-12-30 | |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.0705 | 39360 | -18355 | 2023-03-31 | LOW |
Mahshid (Yilmaz Ph.D.) | Individual Investor | 0.0448 | 25000 | 0 | 2021-12-30 | |
Christensen (Magnus) | Individual Investor | 0.0376 | 21000 | 6000 | 2021-12-30 | |
Hansson (Lennart Ph.D.) | Individual Investor | 0.0358 | 20000 | 0 | 2021-12-30 |
交易计算器
如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Medivir Company profile
关于 Medivir B
Medivir AB是一家总部设在瑞典的制药研究和开发公司,专注于肿瘤学。 公司专注于蛋白酶抑制剂的设计和核苷及核苷酸科学,并将其应用于未满足医疗需求的癌症的治疗方法的开发。 公司的临床管线包括治疗皮肤T细胞淋巴瘤(CTCL)的II期临床研究中的局部组蛋白去乙酰化酶(HDAC)抑制剂remetinostat,治疗实体瘤的I期临床研究中的birinapant与Keytruda(pembrolizumab)联合治疗。 MIV-818,一种基于核苷酸的原药,处于治疗肝癌的一期临床试验中,以及MIV-711,一种治疗骨关节炎的IIa扩展研究中的猫蛋白酶K(CTSK)抑制剂。 此外,公司还与其他机构合作开展了其他研究项目。
Industry: | Bio Therapeutic Drugs |
Lunastigen 5, 2 tr
HUDDINGE
STOCKHOLM 141 22
SE
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球530,000万多名交易者的一份子,选择利用Capital.com进行交易吧。